CHINESE JOURNAL OF DRUG EVALUATION >

2025 , Vol. 42 >Issue 5: 389 - 389-393

DOI: https://doi.org/magtech-2025-07-17-00003

Cost-utility Analysis of Sodium Zirconium Cyclosilicate in the Treatment of Hemodialysis Patients with Chronic Hyperkalemia

Expand
  • 1.Kunming First People′s Hospital， Yunnan Kunming， 650034， China；
    2.Kunming Medical University， Yunnan Kunming 650021， China

Received date: 2025-07-17

  Revised date: 2025-09-19

  Accepted date: 2025-11-27

  Online published: 2025-12-15

Fold

Abstract

Objectives： To evaluate the cost-effectiveness of Standard Treatment versus regular sodium zirconium cyclosilicate (SZC) therapy in hemodialysis patients with chronic hyperkalemia， so as to provide a reference for clinical medication. Methods： The data were obtained from medical records of hemodialysis patients with chronic hyperkalemia treated at a tertiary hospital in Kunming， as well as domestic and international literature. A Markov model was used to conduct a cost-utility analysis comparing two groups—those without specific intervention and those receiving regular SZC therapy—to estimate and compare the costs and quality-adjusted life years (QALYs) generated during the simulated treatment process. One-way sensitivity analysis was performed to assess the impact of key parameters on the results. Results： Under the research model， in the simulation of long-term (10-year) treatment， the treatment cost for hemodialysis patients with chronic hyperkalemia without special intervention was 491 517.27 yuan， with a QALY of 8.15 years. For hemodialysis patients with chronic hyperkalemia who regularly took SZC， the treatment cost was 373 440.10 yuan， with a QALY of 10.83 years. The incremental cost-effectiveness ratio (ICER) was -44 058.65 yuan/QALY， which is below the willingness-to-pay (WTP) threshold. Patients in the SZC group saved 118 077.17 yuan and gained an additional 2.68 QALYs. Conclusion： For hemodialysis patients with chronic hyperkalemia， SZC therapy demonstrates greater economic advantages compared to Standard Treatment.

Key words： ; font-size:medium; ">Sodium zirconium cyclosilicate； Hemodialysis； Hyperkalemia； Cost-utility analysis； Markov

Cite this article

MAO Panpan, SONG Cangsang, ZHANG Hanshu, WANG Guohui, WANG Zidan, LI Xingde . Cost-utility Analysis of Sodium Zirconium Cyclosilicate in the Treatment of Hemodialysis Patients with Chronic Hyperkalemia[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025 , 42(5) : 389 -389-393 . DOI: magtech-2025-07-17-00003

References

 [1] 王玉婷， 陈建华. 慢性肾病药物研发进展[J]. 药学信息， 2022， 11（3）： 234-240.
     [2] Shibata S， Uchida S. Hyperkalemia in patients undergoing hemodialysis：Its pathophysiology and management[J]. Ther Apher Dial， 2022， 26(1)：3-14.
     [3] 李文爽，戴泽琦，孙庆冉，等. 2018—2022年我国中药药物经济学研究文献的质量评价[J]. 中国药房，2023，34(19)：2378-2384.
     [4] 董建华， 王绪臻， 范文静， 等. SZC治疗维持性血液透析患者慢性高钾血症的疗效[J]. 肾脏病与透析肾移植杂志， 2022， 31(1)： 15-20.
     [5] 安兴宇，李兴德，宋沧桑，等. SZC治疗血液透析伴高钾血症的临床研究进展[J]. 中国药物评价，2023，40(6)：512-516.
     [6] Betts KA， Woolley JM， Mu F， et al. The cost of hyperkalemia in the United States[J]. Kidney Intern Reports， 2018， 3(2)： 385-393.
     [7] Chay J， Choo JCJ， Finkelstein EA. Cost-effectiveness of sodium zirconium cyclosilicate for advanced chronic kidney patients in Singapore[J]. Nephrology， 2024， 29(5)： 278-287.
     [8] Lee AJ， Morgan CL， Conway P， et al. Characterisation and comparison of health-related quality of life for patients with renal failure[J]. Curr Med Res Opin， 2005， 21(open in a new window) [11(open in a new window)]：1777-1783.
     [9] Hong SH， Lee JY， Park SK， et al. The utility of 5 hypothetical health states in heart failure using time trade-off (TTO) and EQ-5D-5L in Korea[J]. Clin Drug Investigation， 2018，（38）： 727-736.
     [10] Ni Z， Lu R， Xu X， et al. DIALIZE China：A Phase ⅡⅢb， randomized， placebo-controlled study to reduce predialysis hyperkalemia with sodium zirconium cyclosilicate in Chinese patients[J]. Clin Ther， 2023， 16(18)：1-10.
     [11] Fishbane S， Charytan DM， Chertow GM， et al. Consensus-based recommendations for the management of hyperkalemia in the hemodialysis setting[J]. J Renal Nutr， 2022， 32(4)： e1-e14.
     [12] 安兴宇，李兴德，宋沧桑，等. 环硅酸锆钠治疗慢性肾脏病和血液透析伴高钾血症患者有效性与安全性的meta分析[J]. 中南药学，2024，22(1)：233-239.
     [13] Huang CW， Lee MJ， Lee PT， et al. Low potassium dialysate as a protective factor of sudden cardiac death in hemodialysis patients with hyperkalemia[J]. PLoS One， 2015， 10(10)： e0139886.
     [14] 王志恒， 张梦培， 张皓翔， 等. 应用 Markov 模型对苏黄止咳胶囊治疗慢性阻塞性肺疾病急性加重期住院患者的药物经济学评价 [J]. 中国中药杂志， 2020， 46(10)：2588-2593.
     [15] 王志恒，王晓梅，潘婕，等. 蛭蛇通络胶囊治疗中风(气虚血瘀证)的成本效用分析[J]. 中草药，2021，52(15)：4649-4657.
     [16] Kim K， Fagerstrm J， Chen G， et al. Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden[J]. BMC Nephrology， 2022， 23(1)： 281.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]